Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobicistat/darunavir/emtricitabine/tenofovir alafenamide - Janssen R&D Ireland

Drug Profile

Cobicistat/darunavir/emtricitabine/tenofovir alafenamide - Janssen R&D Ireland

Alternative Names: Cobicistat/darunavir/emtricitabine/GS 7340; Cobicistat/darunavir/emtricitabine/GS 7340 fixed-dose combination - Janssen; Darunavir/cobicistat/emtricitabine/GS-7340; Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide; Darunavir/emtricitabine/GS 7340/cobicistat; Emtricitabine/GS 7340/cobicistat/darunavir; GS 7340/cobicistat/darunavir/emtricitabine; SYMTUZA; Tenofovir alafenamide/cobicistat/darunavir/emtricitabine

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules; Sulfonamides
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; DNA polymerase beta inhibitors; DNA polymerase gamma inhibitors; DNA polymerase II inhibitors; DNA-directed DNA polymerase inhibitors; HIV protease inhibitors; HIV reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 29 Sep 2021 Biomarkers information updated
  • 02 Jul 2021 Janssen R&D initiates completes its phase I trial in HIV-1 infections (In volunteers) in Netherlands (PO, Tablet) in January 2021 (EudraCT2020-003396-18) (NCT04661397)
  • 10 Dec 2020 Janssen R&D initiates enrolment in a phase I trial in HIV-1 infections (In volunteers) in Netherlands (PO, Tablet) in January 2021 (EudraCT2020-003396-18) (NCT04661397)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top